NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AOA Dx

AOA Dx

Private
Denver, ColoradoHealthcare & Life Scienceshttps://aoadx.com/

Last Round

Series A

Oct 12, 2023

Total Funding Raised

$46.8M

Company Overview

AOA Dx is a biotechnology company that develops an AI-enabled multi-omics liquid biopsy platform for the early detection of ovarian cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

ovarian cancer detectionwomen's health diagnosticsbiomarker technologyAKRIVISearly cancer screeningmulti-omic diagnosticliquid biopsyAI-powered diagnosticsclinical decision supportprecision medicineoncology diagnosticsfemtechdiagnostic assayclinical laboratory services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AOA Dx Comps

Public and private peers based on sector, stage, and business model.

AOA Dx comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AOA Dx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 12, 2023
Series AJul 1, 2023
SeedSep 13, 2022
SeedMar 1, 2022
GrantAug 16, 2021
Pre Seed
Jun 28, 2021

Key People

Founding team and executive leadership

Anna Milik Jeter

Chief Regulatory Officer And Co-founder

Founding Team

Oriana Papin-Zoghbi

CEO Co-Founder

Founding Team

victor ramirez

AOA Dx Chief Operating Officer

Executive Team

Zhou Hui

AOA Dx Chief Operating Officer

Executive Team

AOA Dx Investors

Notable investors and investment history

AOA Dx investors
InvestorRounds
SideCar AngelsPre Seed
Canadian Institutes of Health ResearchGrant
TBD AngelsPre Seed
Gore Range CapitalSeries A
Pioneer FundPre Seed
Good Growth CapitalSeries A
AlleyCorpSeed, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2026

    Developing AKRIVIS GD™, an early-stage diagnostic for ovarian cancer.

  • Oct 1, 2025

    Introduced GlycoLocate™ for early cancer detection.

AOA Dx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AOA Dx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AOA Dx's valuation, stock price, and market status.

Firmographic Details

HeadquartersDenver, Colorado
Employee Range55
Year Founded2020
Last FundingOct 12, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.